Cargando…
Dystrophin immunogenicity and requirement in myogenic cells: Paradigm shift in gene therapy for DMD
Autor principal: | Górecki, Dariusz C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691905/ https://www.ncbi.nlm.nih.gov/pubmed/36424805 http://dx.doi.org/10.1002/ctm2.1122 |
Ejemplares similares
-
Non-myogenic tumors display altered expression of dystrophin (DMD) and a high frequency of genetic alterations
por: Luce, Leonela N., et al.
Publicado: (2016) -
Restoration of brain dystrophin using tricyclo-DNA ASOs restores neurobehavioral deficits in DMD mice
por: Karuppasamy, Muthukumar, et al.
Publicado: (2023) -
Dystrophin: The dead calm of a dogma
por: Górecki, Dariusz C.
Publicado: (2016) -
Characterization of brain dystrophins absence and impact in dystrophin-deficient Dmd(mdx) rat model
por: Caudal, Dorian, et al.
Publicado: (2020) -
Screening of Dystrophin Gene Deletions in Egyptian Patients with DMD/BMD Muscular Dystrophies
por: Effat, Laila K., et al.
Publicado: (2000)